Bayer HealthCare Pharmaceuticals' experimental drug BAY 94-9027 met the primary goal of its Phase III trial by helping to prevent internal bleeding in hemophilia A patients when given less frequently compared with standard therapies. The drug also stopped patients' bleeding when bleeding did occur, this article says.

Related Summaries